이스라엘 -
히브리어 -
Ministry of Health
לנלידומיד טבע 10 מג
teva israel ltd - lenalidomide as hydrochloride hydrate - קפסולה קשיחה - lenalidomide as hydrochloride hydrate 10 mg - lenalidomide
이스라엘 -
히브리어 -
Ministry of Health
לנלידומיד טבע 15 מג
teva israel ltd - lenalidomide as hydrochloride hydrate - קפסולה קשיחה - lenalidomide as hydrochloride hydrate 15 mg - lenalidomide
이스라엘 -
히브리어 -
Ministry of Health
לנלידומיד טבע 2.5 מג
teva israel ltd - lenalidomide as hydrochloride hydrate - קפסולה קשיחה - lenalidomide as hydrochloride hydrate 2.5 mg - lenalidomide
이스라엘 -
히브리어 -
Ministry of Health
לנלידומיד טבע 20 מג
teva israel ltd - lenalidomide as hydrochloride hydrate - קפסולה קשיחה - lenalidomide as hydrochloride hydrate 20 mg - lenalidomide
이스라엘 -
히브리어 -
Ministry of Health
לנלידומיד טבע 25 מג
teva israel ltd - lenalidomide as hydrochloride hydrate - קפסולה קשיחה - lenalidomide as hydrochloride hydrate 25 mg - lenalidomide
이스라엘 -
히브리어 -
Ministry of Health
לנלידומיד טבע 5 מג
teva israel ltd - lenalidomide as hydrochloride hydrate - קפסולה קשיחה - lenalidomide as hydrochloride hydrate 5 mg - lenalidomide
이스라엘 -
히브리어 -
Ministry of Health
לנלידומיד טבע 7.5 מג
teva israel ltd - lenalidomide as hydrochloride hydrate - קפסולה קשיחה - lenalidomide as hydrochloride hydrate 7.5 mg - lenalidomide
이스라엘 -
히브리어 -
Ministry of Health
רבלימיד 5 מג
neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 5 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.
이스라엘 -
히브리어 -
Ministry of Health
רבלימיד 5 מג
neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 5 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.
이스라엘 -
히브리어 -
Ministry of Health
רבלימיד 10 מג
neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 10 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.